Meeting
2020 ASCO Virtual Scientific Program
Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors.
Authors
John Sarantopoulos
Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio, San Antonio, TX
John Sarantopoulos , Devalingam Mahalingam , Neelesh Sharma , Renuka V. Iyer , Wen Wee Ma , Manmeet Singh Ahluwalia , Saramarie Johnson , Andrei Purmal , Polina Shpigotskaya , Ann Hards , Andrey Leonov , Katerina Gurova , Andrei Gudkov , Kristina Zakurdaeva , Langdon L. Miller , Afshin Dowlati
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT01905228
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3583)
DOI
10.1200/JCO.2020.38.15_suppl.3583
Abstract #
3583
Poster Bd #
313
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
First Author: Mikhail Fedyanin
Poster
2020 ASCO Virtual Scientific Program
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.
First Author: Xing Zhang
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
First Author: Drew W. Rasco
Poster
2013 ASCO Annual Meeting
A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.
First Author: Monica Arnedos